Aelix Therapeutics
Developing novel vaccines to cure HIV infection.
Launch date
Employees
Market cap
-
Enterprise valuation
€46—69m (Dealroom.co estimates Jan 2016.)
Company register number B66655598
Barcelona Catalonia (HQ & founding location)
Financials
Estimates*
EUR | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|
Revenues | - | 1.6m | 1.8m | 1.1m | 1.3m |
% growth | - | - | 13 % | (37 %) | 15 % |
EBITDA | (<1m) | <1m | (1.6m) | (2.0m) | (2.5m) |
% EBITDA margin | - | 3 % | (89 %) | (176 %) | (191 %) |
Profit | (<1m) | (<1m) | (<1m) | (<1m) | (1.7m) |
% profit margin | - | (1 %) | (6 %) | (64 %) | (128 %) |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
€11.5m | Series A | ||
N/A | €50.0k | Grant | |
N/A | $2.2m | Late VC | |
Total Funding | €13.5m |
Recent News about Aelix Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.